Author

R. Rappuoli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 13 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 15 Research Focus:host-pathogen & immune response· 10 Organism:human· 9 Assay:proteomics· 6 Research Focus:cell type annotation· 4 Research Focus:drug response / drug discovery· 4 Organism:non-human primate· 3 Research Focus:cell-cell communication· 2

Frequent Co-Authors

E. Andreano· 11 shared I. Paciello· 10 shared E. Pantano· 9 shared C. Sala· 8 shared E. Montomoli· 7 shared G. Piccini· 7 shared N. Manganaro· 7 shared P. Pileri· 7 shared

Activity by Year

2020-2024 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

11 shared papersImmunology

E. Andreano

Mutual co-authors in cluster

Author profile →

15 papers

Recent·Most cited

B cell maturation restored ancestral germlines to control Omicron BA.2.86

I. Paciello, G. Pierleoni, E. Pantano, G. Antonelli, P. Pileri, G. Maccari, D. Cardamone, G. Realini, F. Perrone, M. M. Neto, S. Pozzessere, M. Fabbiani, F. Panza, I. Rancan, M. Tumbarello, , E. Andreano

The paper analyzes neutralizing antibodies from vaccinated and hybrid immune individuals to show that restored B cell germlines enhance neutralization against SARS-CoV-2 variants like BA.2.86.

bioRxiv · Mar 3, 2024 · PreprintImmunology

Anti-capsule human monoclonal antibodies protect against hypervirulent and pandrug-resistant Klebsiella pneumoniae

E. Roscioli, V. Zucconi Galli Fonseca, S. S. Bosch, I. Paciello, G. Maccari, G. Batani, S. Stazzoni, G. Cardinali, G. Tiseo, C. Giordano, Y. Shen, L. Capoccia, M. Ridelfi, M. Troisi, N. Manganaro, , R. Rappuoli

This study isolates human monoclonal antibodies against hypervirulent, pandrug-resistant Klebsiella pneumoniae and identifies capsule-specific antibodies as protective against bloodstream infection.

bioRxiv · Feb 14, 2024 · PreprintMicrobiology

High-resolution map of the Fc-functions mediated by COVID-19 neutralizing antibodies

I. Paciello, G. Maccari, E. Pantano, E. Andreano, R. Rappuoli

This study maps Fc-functions of 482 SARS-CoV-2 neutralizing antibodies, showing that potent neutralizers may have weak Fc-functions and that Fc-functions are influenced by epitope targeting and B cell germlines.

bioRxiv · Jul 10, 2023Immunology

High-throughput bactericidal assays for monoclonal antibody screening against antimicrobial resistant Neisseria gonorrhoeae

S. Stazzoni, M. Troisi, V. Abbiento, C. Sala, E. Andreano, R. Rappuoli

This study develops high-throughput bactericidal assays to screen monoclonal antibodies against antimicrobial-resistant Neisseria gonorrhoeae, identifying potent antibodies validated by conventional methods.

bioRxiv · May 10, 2023 · PreprintMicrobiology

mRNA vaccines and hybrid immunity use different B cell germlines to neutralize Omicron BA.4 and BA.5

E. Andreano, I. Paciello, G. Pierleoni, G. Maccari, G. Antonelli, V. Abbiento, P. Pileri, L. Benincasa, G. Giglioli, G. Piccini, C. De Santi, C. Sala, D. Medini, E. Montomoli, P. Maes, R. Rappuoli

The paper compares neutralizing antibodies against Omicron BA.4 and BA.5 from mRNA-vaccinated individuals and those with hybrid immunity, finding differences in epitope targeting and B cell germlines used.

bioRxiv · Aug 4, 2022 · PreprintImmunology

SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly

A. Onnis, E. Andreano, C. Cassioli, E. Pantano, V. Abbiento, G. Marotta, R. Rappuoli, C. T. Baldari

This study shows SARS-CoV-2 Spike protein inhibits CTL immune synapse formation by binding ACE2, reducing target cell killing.

bioRxiv · May 20, 2022Immunology

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

J. L. Torres, G. Ozorowski, E. Andreano, H. Liu, J. Copps, G. Piccini, L. Donnici, M. Conti, C. Planchais, D. Planas, N. Manganaro, E. Pantano, I. Paciello, P. Pileri, T. Bruel, , A. B. Ward

The paper evaluates the potency of mAb J08 against SARS-CoV-2 variants using cell-based assays and cryo-EM, showing its resistance to escape mutations and broad binding capability.

Proceedings of the National Academy of Sciences · May 12, 2022Peer-reviewedImmunology

COVID-19 mRNA third dose induces a unique hybrid immunity-like antibody response

E. Andreano, I. Paciello, G. Pierleoni, G. Piccini, V. Abbiento, G. Antonelli, P. Pileri, N. Manganaro, E. Pantano, G. Maccari, S. Marchese, L. Donnici, L. Benincasa, G. Giglioli, M. Leonardi, , R. Rappuoli

This study examines how a third mRNA vaccine dose enhances neutralizing antibody responses against SARS-CoV-2 variants by expanding specific B cell germlines and altering the antibody repertoire.

bioRxiv · May 9, 2022 · PreprintImmunology

Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine

P. S. Arunachalam, Y. Feng, U. Ashraf, M. Hu, V. V. Edara, V. I. Zarnitsyna, P. P. Aye, N. Golden, K. W. M. Green, B. M. Threeton, N. J. Maness, B. J. Beddingfield, R. P. Bohm, J. Dufour, K. Russell-Lodrigue, , B. Pulendran

This study shows that an adjuvanted subunit vaccine provides durable protection against SARS-CoV-2 Omicron in non-human primates, with strong neutralizing antibodies and memory T/B cells after booster doses.

bioRxiv · Mar 18, 2022 · PreprintImmunology

Hybrid immunity improves B cell frequency, antibody potency and breadth against SARS-CoV-2 and variants of concern

E. Andreano, I. Paciello, G. Piccini, N. Manganaro, P. Pileri, I. Hyseni, M. Leonardi, E. Pantano, V. Abbiento, L. Benincasa, G. Giglioli, C. De Santi, M. Fabbiani, I. Rancan, M. Tumbarello, , R. Rappuoli

This study compares B cell responses in naive and convalescent individuals after SARS-CoV-2 vaccination, showing convalescents have higher frequency and broader neutralizing antibody responses against variants.

bioRxiv · Aug 12, 2021 · PreprintImmunology

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

A. C. Walls, M. C. Miranda, M. N. Pham, A. Schaefer, A. Greaney, P. S. Arunachalam, M.-J. Navarro, M. A. Tortorici, K. Rogers, M. A. O'Connor, L. Shireff, D. E. Ferrell, N. Brunette, E. Kepl, J. E. Bowen, , Veesler

This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.

bioRxiv · Mar 15, 2021Immunology

Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

P. S Arunachalam, A. C. Walls, N. Golden, C. Atyeo, S. Fischinger, C. Li, P. Aye, M. J. Navarro, L. Lai, V. V. Edara, K. Roltgen, K. Rogers, L. Shirreff, D. E. Ferrell, S. Wrenn, , Coffma

This study evaluates adjuvants for a subunit SARS-CoV-2 nanoparticle vaccine in non-human primates, showing durable neutralizing antibody responses and protection against infection.

bioRxiv · Feb 10, 2021 · PreprintImmunology

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma

E. Andreano, G. Piccini, D. Licastro, L. Casalino, N. V. Johnson, I. Paciello, S. Dal Monego, E. Pantano, N. Manganaro, A. Manenti, R. Manna, E. Casa, I. Hyseni, L. Benincasa, E. Montomoli, , R. Rappuoli

This study shows that three mutations in SARS-CoV-2 allowed it to escape neutralization by a highly neutralizing convalescent plasma.

bioRxiv · Dec 28, 2020Immunology

Extremely potent human monoclonal antibodies from convalescent Covid-19 patients

E. Andreano, E. Nicastri, I. Paciello, P. Pileri, N. Manganaro, G. Piccini, A. Manenti, E. Pantano, A. Kabanova, M. Troisi, F. Vacca, D. Cardamone, C. De Santi, L. Benincasa, C. Agrati, , R. Rappuoli

The paper isolates extremely potent human monoclonal antibodies from convalescent Covid-19 patients, effective against SARS-CoV-2 at low concentrations.

bioRxiv · Oct 7, 2020Immunology

Identification of neutralizing human monoclonal antibodies from Italian Covid-19 convalescent patients

E. Andreano, E. Nicastri, I. Paciello, P. Pileri, N. Manganaro, G. Piccini, A. Manenti, M. Troisi, F. Vacca, E. Pantano, C. De Santi, D. Cardamone, A. Kabanova, C. Agrati, C. Castilletti, , R. Rappuoli

The paper isolates neutralizing human monoclonal antibodies from Covid-19 convalescent patients for therapeutic and prophylactic interventions.

bioRxiv · May 5, 2020 · PreprintImmunology